Helius Med Technologies Inc Stock Price, News & Analysis

Helius Medical Technologies (Nasdaq: HSDT) announced that CEO Dane C. Andreeff will present at the Dawson James Small Cap Growth Conference on October 21, 2021, from 11:00-11:20 AM ET. Interested parties can access the live webcast via this link, which will also be available for 30 days post-event. Helius focuses on neurological wellness, developing the Portable Neuromodulation Stimulator (PoNS™), an FDA-authorized device for treating gait deficits related to multiple sclerosis and traumatic brain injury.

Helius Medical Technologies (HSDT) announced that CEO Dane C. Andreeff will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 1:35 PM ET. The event will be available via live webcast and archived on their website for 30 days. Helius focuses on neurological wellness and aims to develop non-invasive technologies, including its Portable Neuromodulation Stimulator (PoNS™), designed for treating gait deficits and balance issues associated with neurological conditions.

Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Buckman, who brings over 30 years of experience in the medical device sector, will serve as Chair of the Audit Committee and a member of the Compensation and Nominating & Governance Committees. He is currently President, North America for LivaNova and has held leadership roles in various medical device companies. His expertise is expected to enhance Helius' growth, particularly with its novel treatment approaches for chronic neurological conditions.

Helius Medical Technologies (Nasdaq: HSDT) announced participation in the H.C. Wainwright Annual Global Life Sciences Conference from September 13-15, 2021. Management's presentation will be available on-demand starting September 13 at 7:00 a.m. Eastern Time, with investor meetings scheduled during the conference. Helius focuses on neurological wellness and develops the Portable Neuromodulation Stimulator (PoNS™), an innovative device for treating gait deficits associated with multiple sclerosis and mild traumatic brain injuries. For more information, visit heliusmedical.com.

Helius Medical Technologies (Nasdaq:HSDT) announced its voluntary delisting from the Toronto Stock Exchange (TSX), with the last trading day expected on September 9, 2021. The decision comes as the company believes that the trading volume does not justify the costs and efforts associated with maintaining the TSX listing, especially since it is already listed on Nasdaq. This move aims to redirect resources towards business advancement while ensuring good liquidity for stockholders. No shareholder approval is required for this delisting.

Helius Medical Technologies (Nasdaq:HSDT) announced that its PoNS™ device has received Breakthrough Designation from the U.S. FDA for treating dynamic gait and balance deficits due to stroke. This device aims to assist patients aged 22 and older as part of a supervised therapeutic exercise program. Strokes affect approximately 7 million Americans, with over 80% experiencing gait impairment. The Breakthrough designation enables more efficient interactions with the FDA and prioritized review, which could enhance patient access to this non-drug treatment option.

Helius Medical Technologies (Nasdaq:HSDT) reported a net loss of $6 million for Q2 2021, compared to a $3.4 million loss in Q2 2020. Revenue fell to $71,000 from $133,000 year-over-year. The operating loss increased 66% to $6.2 million, driven by a $1.9 million rise in non-cash stock-based compensation. The company ended the quarter with $7.4 million in cash, up from $3.3 million in December 2020. Despite challenges, Helius is focused on U.S. commercialization of its PoNS device, targeting MS patients with gait deficits, and aims to begin operations in early 2022.

Helius Medical Technologies, Inc. (HSDT) announced the approval of an equity award for a new employee under its 2021 Inducement Plan, effective August 10, 2021. The award grants an option to purchase 2,000 shares of Class A common stock at an exercise price of $15.39 per share, which is the closing price on the grant date. The options will vest over four years, contingent upon the new hire's ongoing employment. This announcement complies with Nasdaq Listing Rule 5635(c)(4), which mandates public disclosure of non-stockholder approved equity awards.

Helius Medical Technologies (Nasdaq:HSDT) has launched a new website to enhance resources for U.S.-based patients and physicians regarding its PoNS Treatment. As part of its pre-commercial activities, the company aims to raise awareness and educate key clinicians about the PoNS device, which is designed for treating gait deficits associated with multiple sclerosis. The device is expected to be commercialized in Q1 2022. The company faces several challenges, including securing Medicare coverage and building a commercial infrastructure.